{
    "table_name": "CPTAC.QUANT_PHOSPHOPROTEOME_AML_EX_VIVO_DRUG_RESPONSE_SORAFENIB_TREATMENT_PDC_CURRENT",
    "table_fullname": "CPTAC_PDC.CPTAC.QUANT_PHOSPHOPROTEOME_AML_EX_VIVO_DRUG_RESPONSE_SORAFENIB_TREATMENT_PDC_CURRENT",
    "column_names": [
        "aliquot_submitter_id",
        "study_name",
        "case_id",
        "refseq_id",
        "protein_abundance_log2ratio",
        "aliquot_run_metadata_id",
        "phosphorylation_sites",
        "sample_id",
        "aliquot_id"
    ],
    "column_types": [
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "FLOAT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT"
    ],
    "description": [
        null,
        null,
        null,
        null,
        null,
        null,
        null,
        null,
        null
    ],
    "sample_rows": [
        {
            "case_id": "ecbde1d1-d1d9-4de5-913d-090a0571edd9",
            "sample_id": "c00046d2-ffee-43d8-a72f-64a187590a7b",
            "aliquot_id": "d9a038c8-92b3-4fff-afeb-799d93b97841",
            "aliquot_submitter_id": "15-00276-1",
            "aliquot_run_metadata_id": "0c7495c0-2773-4f0a-aef6-ad497c9e1249",
            "study_name": "AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome",
            "protein_abundance_log2ratio": -2.4666,
            "refseq_id": "NP_000436.2",
            "phosphorylation_sites": "s1622"
        },
        {
            "case_id": "ecbde1d1-d1d9-4de5-913d-090a0571edd9",
            "sample_id": "c00046d2-ffee-43d8-a72f-64a187590a7b",
            "aliquot_id": "d9a038c8-92b3-4fff-afeb-799d93b97841",
            "aliquot_submitter_id": "15-00276-1",
            "aliquot_run_metadata_id": "0c7495c0-2773-4f0a-aef6-ad497c9e1249",
            "study_name": "AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome",
            "protein_abundance_log2ratio": -4.0065,
            "refseq_id": "NP_001001.2",
            "phosphorylation_sites": "s235s236"
        },
        {
            "case_id": "ecbde1d1-d1d9-4de5-913d-090a0571edd9",
            "sample_id": "c00046d2-ffee-43d8-a72f-64a187590a7b",
            "aliquot_id": "d9a038c8-92b3-4fff-afeb-799d93b97841",
            "aliquot_submitter_id": "15-00276-1",
            "aliquot_run_metadata_id": "0c7495c0-2773-4f0a-aef6-ad497c9e1249",
            "study_name": "AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome",
            "protein_abundance_log2ratio": -3.1567,
            "refseq_id": "NP_001070729.2",
            "phosphorylation_sites": "s215"
        },
        {
            "case_id": "ecbde1d1-d1d9-4de5-913d-090a0571edd9",
            "sample_id": "c00046d2-ffee-43d8-a72f-64a187590a7b",
            "aliquot_id": "d9a038c8-92b3-4fff-afeb-799d93b97841",
            "aliquot_submitter_id": "15-00276-1",
            "aliquot_run_metadata_id": "0c7495c0-2773-4f0a-aef6-ad497c9e1249",
            "study_name": "AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome",
            "protein_abundance_log2ratio": -1.0402,
            "refseq_id": "NP_001092.1",
            "phosphorylation_sites": "y294"
        },
        {
            "case_id": "ecbde1d1-d1d9-4de5-913d-090a0571edd9",
            "sample_id": "c00046d2-ffee-43d8-a72f-64a187590a7b",
            "aliquot_id": "d9a038c8-92b3-4fff-afeb-799d93b97841",
            "aliquot_submitter_id": "15-00276-1",
            "aliquot_run_metadata_id": "0c7495c0-2773-4f0a-aef6-ad497c9e1249",
            "study_name": "AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome",
            "protein_abundance_log2ratio": -4.5949,
            "refseq_id": "NP_001098549.2",
            "phosphorylation_sites": "s333"
        }
    ]
}